Roth Bradley J, Shumaker Andrew D, Bajic Petar, Vij Sarah C, Bortoletto Pietro E, Lundy Scott D
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Urology. 2025 Apr;198:40-46. doi: 10.1016/j.urology.2024.12.050. Epub 2025 Jan 10.
To determine if routine pre-vasectomy sperm cryopreservation is more cost-effective than fertility restoration for patients who desire additional children following vasectomy?
A scoping review was performed to collect published data regarding efficacy and outcomes of cryopreservation, vasectomy reversal, surgical sperm retrieval, and assisted reproductive technologies (ART). Cost data were collected from US-based facilities performing cryopreservation and andrology clinical care. A cost-effectiveness model was generated using TreeAge Pro cost-effectiveness modeling software with 3 different variations representing a balanced scenario with median expected parameter values, a scenario with assumptions/variables favoring pre-vasectomy cryopreservation, and a scenario favoring fertility restoration. The primary outcome was cost per live birth and the secondary outcome was overall live birth rate.
Pre-vasectomy cryopreservation cost ($140,247, range $48,232-$552,807 per live birth) was significantly higher than with fertility restoration ($20,458 range $20,458-$30,698). Surprisingly, pregnancy success rates appeared to be incrementally higher in the fertility restoration group (62%, range 44%-66%) compared to cryopreservation (46%, range 36%-58%) when using published literature values.
Routine sperm cryopreservation prior to vasectomy conveys a significantly higher cost to patients and the healthcare system and does not appear to increase live birth rate compared to fertility restoration with sperm retrieval or vasectomy reversal. Patients without fertility risk factors should be counseled on the added cost and need for ART with pre-vasectomy cryopreservation but should still be allowed to proceed if desired.
对于输精管结扎术后希望再育的患者,确定常规输精管结扎术前精子冷冻保存是否比恢复生育能力更具成本效益?
进行了一项范围综述,以收集有关冷冻保存、输精管复通术、手术取精及辅助生殖技术(ART)的疗效和结果的已发表数据。成本数据收集自美国进行冷冻保存和男科临床护理的机构。使用TreeAge Pro成本效益建模软件生成了一个成本效益模型,有3种不同变体,分别代表具有中位数预期参数值的平衡情景、有利于输精管结扎术前冷冻保存的假设/变量情景以及有利于恢复生育能力的情景。主要结局是每例活产的成本,次要结局是总体活产率。
输精管结扎术前冷冻保存的成本(每例活产140,247美元,范围为48,232 - 552,807美元)显著高于恢复生育能力的成本(20,458美元,范围为20,458 - 30,698美元)。令人惊讶的是,使用已发表文献值时,恢复生育能力组的妊娠成功率(62%,范围为44% - 66%)似乎比冷冻保存组(46%,范围为36% - 58%)略有更高。
输精管结扎术前常规精子冷冻保存给患者和医疗保健系统带来的成本显著更高,与通过取精或输精管复通术恢复生育能力相比,似乎并未提高活产率。对于没有生育风险因素的患者,应告知其输精管结扎术前冷冻保存的额外成本以及对ART的需求,但如果患者有此意愿,仍应允许其进行。